Yale trial could mark 1st step to preventive treatment in Parkinson’s

[Farooqji]

parkinsonsnewstoday.com/new...

[jeffreyn]

"the coming trial will evaluate whether being treated with the anti-TNF therapy Humira can prevent Parkinson’s-associated symptoms in those with RBD."

[JayPwP]

Do they now know the cause of PD, to prevent it?

[park_bear in reply to JayPwP]

healthunlocked.com/cure-par....

[crewmanwhite]

Nasty dangerous stuff

[gomelgo]

Bolt_Upright have you seen this?

[Bolt_Upright in reply to gomelgo]

Yes. I shared this post on FB.

[Bolt_Upright]

Article about 2 women that may have got PD after taking Humira: Parkinsonism and dystonia associated with adalimumab (Humira) 2011 movementdisorders.onlinelib...

[gomelgo in reply to Bolt_Upright]

If I can't pronounce it, I'm not taking it.

[chartist]

From the frying pan into Humira. Humira has serious side effects that include death :

drugs.com/sfx/humira-side-e...

A relevant quote :

' Patients treated with adalimumab are at increased risk of infection, some of which may become serious and lead to hospitalization or death. These infections have included TB, invasive fungal infections, bacterial, viral, and those caused by opportunistic pathogens including Legionella and Listeria. The risks and benefits of therapy should be carefully considered prior to treatment initiation in patients with chronic or recurrent infection. Evaluate for latent TB and treat if necessary prior to initiating therapy. Monitor patients closely for signs and symptoms of infection during and after treatment, including the possible development of TB in patients who tested negative prior to treatment. Consider empirical antifungal therapy in at-risk patients who develop severe systemic illness. Lymphoma and other malignancies, some fatal, have been reported in pediatric and adolescent patients treated with tumor necrosis factor (TNF) blockers such as adalimumab. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), usually fatal, have been reported in patients treated with TNF blockers including adalimumab, primarily in adolescent and young adult males with Crohn disease and ulcerative colitis. '

FMT seems much much safer, yet Yale is going to test a drug that has potential for very serious side effects over relatively safe FMT. I wonder why that is?

Art